Stevanato Group S.p.A. $STVN Stock Position Raised by Cooper Investors PTY Ltd.

Key Points

• Cooper Investors PTY Ltd. boosted its stake in Stevanato Group by 17.8% to 695,245 shares in Q4 (adding 104,937 shares), making STVN its 5th-largest holding (~4.6% of the firm's portfolio) and worth about $13.99 million (≈0.23% of the company) at period end.
• Several analysts have cut targets or downgraded STVN recently (Morgan Stanley, KeyCorp, Citigroup lowered targets; Weiss moved to a sell), but MarketBeat's consensus remains a Moderate Buy (1 Strong Buy, 3 Buy, 1 Hold, 1 Sell).
• Stevanato Group trades between a 12-month low/high of €12.89/€28.00, has a market cap of $4.06 billion, a P/E of 23.10, and 50-/200-day moving averages of €15.79 and €20.73 respectively.

Cooper Investors PTY Ltd. boosted its stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) by 17.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 695,245 shares of the company's stock after purchasing an additional 104,937 shares during the period. Stevanato Group makes up approximately 4.6% of Cooper Investors PTY Ltd.'s holdings, making the stock its 5th largest position. Cooper Investors PTY Ltd. owned about 0.23% of Stevanato Group worth $13,988,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of STVN. Farther Finance Advisors LLC bought a new stake in shares of Stevanato Group in the third quarter worth $44,000. First Horizon Corp purchased a new stake in Stevanato Group during the third quarter valued at $50,000. State of Wyoming lifted its holdings in Stevanato Group by 39,216.7% in the second quarter. State of Wyoming now owns 2,359 shares of the company's stock valued at $58,000 after acquiring an additional 2,353 shares during the period. Quantbot Technologies LP purchased a new position in Stevanato Group in the third quarter worth about $68,000. Finally, Van Berkom & Associates Inc. boosted its position in Stevanato Group by 50.6% in the third quarter. Van Berkom & Associates Inc. now owns 3,615 shares of the company's stock worth $93,000 after purchasing an additional 1,215 shares during the last quarter.

Stevanato Group Price Performance

NYSE STVN opened at €13.40 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.26 and a debt-to-equity ratio of 0.23. Stevanato Group S.p.A. has a 12 month low of €12.89 and a 12 month high of €28.00. The stock has a market cap of $4.06 billion, a price-to-earnings ratio of 23.10, a PEG ratio of 1.20 and a beta of 0.57. The company's 50 day moving average is €15.79 and its two-hundred day moving average is €20.73.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on STVN. Morgan Stanley reduced their price target on shares of Stevanato Group from $24.00 to $19.00 and set an "equal weight" rating for the company in a research report on Friday, March 6th. Wall Street Zen cut shares of Stevanato Group from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. KeyCorp dropped their price target on shares of Stevanato Group from $37.00 to $32.00 and set an "overweight" rating on the stock in a research note on Thursday, March 5th. Weiss Ratings lowered Stevanato Group from a "hold (c-)" rating to a "sell (d+)" rating in a research note on Wednesday, March 11th. Finally, Citigroup lowered their target price on Stevanato Group from $32.00 to $26.00 and set a "buy" rating on the stock in a research report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Stevanato Group has a consensus rating of "Moderate Buy".

Stevanato Group Company Profile

Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.

In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.

Want to see what other hedge funds are holding STVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Stevanato Group S.p.A. (NYSE:STVN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.